Cargando…

The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa

BACKGROUND & OBJECTIVE: Pseudomonas aeruginosa is an opportunistic pathogen and one of the most common causes of nosocomial infections. This bacterium's antibiotic resistance to the common fluoroquinolone antibiotics, especially ciprofloxacin, is due to mutations in the gyrA and parC genes....

Descripción completa

Detalles Bibliográficos
Autores principales: Arabameri, Nasibeh, Heshmatipour, Zoheir, Eftekhar Ardebili, Shima, Jafari Bidhendi, Zeinab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Society of Pathology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463757/
https://www.ncbi.nlm.nih.gov/pubmed/34567192
http://dx.doi.org/10.30699/IJP.2021.520570.2542
_version_ 1784572464772153344
author Arabameri, Nasibeh
Heshmatipour, Zoheir
Eftekhar Ardebili, Shima
Jafari Bidhendi, Zeinab
author_facet Arabameri, Nasibeh
Heshmatipour, Zoheir
Eftekhar Ardebili, Shima
Jafari Bidhendi, Zeinab
author_sort Arabameri, Nasibeh
collection PubMed
description BACKGROUND & OBJECTIVE: Pseudomonas aeruginosa is an opportunistic pathogen and one of the most common causes of nosocomial infections. This bacterium's antibiotic resistance to the common fluoroquinolone antibiotics, especially ciprofloxacin, is due to mutations in the gyrA and parC genes. This study aimed to investigate the effect of the mutation in (gyrA, parC) on ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa. METHODS: A total of 140 clinical samples were collected from hospitals. The samples were identified by standard biochemical tests, and the antibiotic resistance was investigated by the disk diffusion method. DNA was extracted from 30 isolates, and PCR was performed. PCR-sequencing was carried out to assess gyrA and parC mutations in drug-resistant isolates. NCBI-Blast and MEGA7 software was used to analyze the nucleotide sequences. RESULTS: 30 clinical isolates were 80% resistant to ciprofloxacin; meanwhile, in 21 samples, mutations were observed. 87/5% of mutations were related to gyrA (Thr83 → Ile), 79/16 % parC (Ser87 → Leu), and 4/18% (Glu91 → Lys). The antibiotic resistance to ciprofloxacin and mutations in gyrA and parC genes in resistant isolates are significantly related to each other (P<0.05). CONCLUSION: The mutations in the gyrA and parC genes play an essential role in resistance to ciprofloxacin in clinical isolates of Pseudomonas aeruginosa.
format Online
Article
Text
id pubmed-8463757
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Iranian Society of Pathology
record_format MEDLINE/PubMed
spelling pubmed-84637572021-09-25 The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa Arabameri, Nasibeh Heshmatipour, Zoheir Eftekhar Ardebili, Shima Jafari Bidhendi, Zeinab Iran J Pathol Original Article BACKGROUND & OBJECTIVE: Pseudomonas aeruginosa is an opportunistic pathogen and one of the most common causes of nosocomial infections. This bacterium's antibiotic resistance to the common fluoroquinolone antibiotics, especially ciprofloxacin, is due to mutations in the gyrA and parC genes. This study aimed to investigate the effect of the mutation in (gyrA, parC) on ciprofloxacin resistance in clinical isolates of Pseudomonas aeruginosa. METHODS: A total of 140 clinical samples were collected from hospitals. The samples were identified by standard biochemical tests, and the antibiotic resistance was investigated by the disk diffusion method. DNA was extracted from 30 isolates, and PCR was performed. PCR-sequencing was carried out to assess gyrA and parC mutations in drug-resistant isolates. NCBI-Blast and MEGA7 software was used to analyze the nucleotide sequences. RESULTS: 30 clinical isolates were 80% resistant to ciprofloxacin; meanwhile, in 21 samples, mutations were observed. 87/5% of mutations were related to gyrA (Thr83 → Ile), 79/16 % parC (Ser87 → Leu), and 4/18% (Glu91 → Lys). The antibiotic resistance to ciprofloxacin and mutations in gyrA and parC genes in resistant isolates are significantly related to each other (P<0.05). CONCLUSION: The mutations in the gyrA and parC genes play an essential role in resistance to ciprofloxacin in clinical isolates of Pseudomonas aeruginosa. Iranian Society of Pathology 2021 2021-07-06 /pmc/articles/PMC8463757/ /pubmed/34567192 http://dx.doi.org/10.30699/IJP.2021.520570.2542 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution- 4.0 International License, (https://creativecommons.org/licenses/by/4.0/) which permits Share, copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, even commercially
spellingShingle Original Article
Arabameri, Nasibeh
Heshmatipour, Zoheir
Eftekhar Ardebili, Shima
Jafari Bidhendi, Zeinab
The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa
title The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa
title_full The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa
title_fullStr The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa
title_full_unstemmed The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa
title_short The role of Gene Mutations (gyrA, parC) in Resistance to Ciprofloxacin in Clinical Isolates of Pseudomonas Aeruginosa
title_sort role of gene mutations (gyra, parc) in resistance to ciprofloxacin in clinical isolates of pseudomonas aeruginosa
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8463757/
https://www.ncbi.nlm.nih.gov/pubmed/34567192
http://dx.doi.org/10.30699/IJP.2021.520570.2542
work_keys_str_mv AT arabamerinasibeh theroleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa
AT heshmatipourzoheir theroleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa
AT eftekharardebilishima theroleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa
AT jafaribidhendizeinab theroleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa
AT arabamerinasibeh roleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa
AT heshmatipourzoheir roleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa
AT eftekharardebilishima roleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa
AT jafaribidhendizeinab roleofgenemutationsgyraparcinresistancetociprofloxacininclinicalisolatesofpseudomonasaeruginosa